The Physiological Roles of Amyloid-β Peptide Hint at New Ways to Treat Alzheimer's Disease
Open accessAbstract
Amyloid-ß (Aß) is best known as the misfolded peptide that is involved in the pathogenesis of Alzheimer's disease (AD), and it is currently the primary therapeutic target in attempts to arrest the course of this disease. This notoriety has overshadowed evidence that Aß serves several important physiological functions. Aß is present throughout the lifespan, it has been found in all vertebrates examined thus far, and its molecular sequence shows a high degree of conservation. These features are typical of a factor that contributes significantly to biological fitness, and this suggestion has been supported by evidence of functions that are beneficial for the brain. The putative roles of Aß include protecting the body from infections, repairing leaks in the blood-brain barrier, promoting recovery from injury, and regulating synaptic function. Evidence for these beneficial roles comes from in vitro and in vivo studies, which have shown that the cellular production of Aß rapidly increases in response to a physiological challenge and often diminishes upon recovery. These roles are further supported by the adverse outcomes of clinical trials that have attempted to deplete Aß in order to treat AD. We suggest that anti-Aß therapies will produce fewer adverse effects if the known triggers of Aß deposition (e.g. pathogens, hypertension and diabetes) are addressed first.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Reductions in monomeric amyloid-beta, and by extension oligomeric forms, are not efficacious in the patient populations tested and do not cause substantial plaque removal.
“we conclude that reductions in monomeric Aβ, and by extension, oligomeric forms of Aβ 53 , are not efficacious in the patient populations tested and also do not mediate significant removal of plaque”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 209 · Cited by 314
Research works printed but not linked: 4
- AlzForum (2012a). Bapineuzumab Phase 3: Target Engagement, But No Benefit. Available online at: http://www.alzforum.org/news/conference-coverage/bapineuzumab-phase-3-target-engagement-no-benefit
- AlzForum (2013). Anti-Amyloid Results Show Modest Benefits, Mild Side Effects. Available online at: http://www.alzforum.org/news/conference-coverage/anti-amyloid-results-show-modest-benefits-mild-side-effects
- AlzForum (2014a). Denied Breakthroughs, Researchers Keep Hunting New Therapies. Available online at: http://www.alzforum.org/news/conference-coverage/denied-breakthroughs-researchers-keep-hunting-new-therapies
- D'Andrea M. R. (2014). Bursting Neurons and Fading Memories: An Alternative Hypothesis of the Pathogenesis of Alzheimer's Disease, 1st Edn. New York, NY: Academic Press.
- Authors
- Brothers, H. M., Gosztyla, M. L., & Robinson, S. R.
- Affiliations
- The Ohio State University (US)
- RMIT University (AU)
- Corresponding author
- Robinson, Stephen R.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2018-04-25
- Volume
- 10
- Pages
- 118-118
- ISSN
- 1663-4365 (ISSN-L)
- PMC
- PMC5996906
- OpenAlex
- W2802918776
- Cited by
- 314
- References
- 209
- Citations by year
- 2026: 17 · 2025: 21 · 2024: 36 · 2023: 33 · 2022: 54 · 2021: 51 · 2020: 67 · 2019: 30 · 2018: 4 · 2013: 1
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Frontiers in Aging Neuroscience (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RMIT Research Repository (RMIT University Library) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Ohio State University
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- amyloid-beta, Alzheimer's disease, anti-amyloid therapy, blood-brain barrier repair, synaptic function, infection defense, injury recovery, hypertension, diabetes mellitus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review